T1	intervention 19 45	gemcitabine plus docetaxel
T2	control 53 80	capecitabine plus docetaxel
T3	eligibility 272 310	patients with metastatic breast cancer
T4	outcome-Measure 691 716	time to progression (TtP)
T6	total-participants 851 854	475
T7	total-participants 893 896	324
T8	outcome 1059 1082	discontinued due to AEs
T9	cv-bin-percent 1054 1057	28%
T10	iv-bin-percent 1101 1106	18.0%
T11	outcome 1120 1123	TtP
T14	outcome 1209 1211	OS
T18	iv-bin-abs 1372 1374	72
T19	intervention-participants 1378 1381	207
T20	iv-bin-percent 1383 1388	34.8%
T21	cv-bin-abs 1398 1400	78
T22	control-participants 1404 1407	191
T23	cv-bin-percent 1409 1414	40.8%
T12	outcome 1417 1433	TtP, OS, and ORR
T13	outcome 1513 1520	fatigue
T15	outcome 1522 1536	hepatotoxicity
T16	outcome 1538 1549	neutropenia
T17	outcome 1555 1571	thrombocytopenia
T24	outcome 1580 1599	febrile neutropenia
T25	outcome 1616 1634	hand-foot syndrome
T26	outcome 1636 1661	gastrointestinal toxicity
T27	outcome 1667 1676	mucositis
T28	outcome 1310 1313	ORR
T5	outcome-Measure 749 776	overall response rate (ORR)
T29	outcome-Measure 778 799	overall survival (OS)
T30	outcome-Measure 805 825	adverse events (AEs)
